Cost savings have consistently provided 200-300 bps of year-over-year margin benefit each quarter since fiscal 2012. Additionally, the company's focus on improving product portfolio through strategic initiatives, which enables it to concentrate on its fast-growing businesses, is aiding bottom line. As part of this, the company adheres to a systematic acquisition and divestiture plan to streamline portfolio, which is evident from the recent agreement to buy consumer-health business of Germany-based Merck KGaA, which will replace P&G's joint venture with Teva Pharmaceutical Industries — PGT Healthcare joint venture. Given the mixed discussion above, we would prefer to wait and see what's in store for this consumer goods company in the quarter to-be reported. What the Zacks Model Unveils Our proven model does not conclusively show that Procter & Gamble is likely to beat earnings estimates this quarter.